首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 基因治療學和RNAi > 歐洲生物藥品市場的新治療市場
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

歐洲生物藥品市場的新治療市場

Emerging Therapeutic Segments in the European Biopharmaceutical Markets

出版商 Frost & Sullivan
出版日期 2009年08月 商品編碼 98072
內容資訊 英文  
價格
US $ 6500 Web Access (Regional License)
US $ 7000 Hard Copy & Web Access (Regional License)


歐洲生物藥品市場的新治療市場 是由出版商Frost & Sullivan在2009年08月所出版的。 這份英文市場調查報告書價格從美金6500起跳。

目錄

Abstract

The research services provides an analysis of the European markets for emerging therapeutic areas such as antisense therapy, gene therapy and cell therapy. The research services segments the market based on the drug classes. The research analyses the challenges faced by the biopharmaceutical industry and the potential uses for the emerging therapeutic areas. The research also provides market sizes for the total biopharmaceutical markets and the market for emerging therapeutic areas.

Table of Contents

1. EXECUTIVE SUMMARY

  • Introduction
    • 1. Summary

2. MARKET OVERVIEW

3. MARKET ANALYSIS

  • Market Introduction
    • 1. Introduction
    • 2. Measurements
    • 3. Main Classes of Biopharmaceuticals
    • 4. Recent Product Approvals in Europe
    • 5. Competitive Structure
  • Research Scope and Methodology
    • 1. Scope and Segmentation
    • 2. Research Methodology
  • Market Trends
    • 1. Industry Challenges
    • 2. Market Drivers
    • 3. Market Restraints
  • Pipeline Analysis
    • 1. Antisense Therapies
    • 2. Gene Therapies
    • 3. Cell Therapies

4. REVENUE ANALYSIS

  • Total Market Forecasts
    • 1. Revenue Forecasts
  • Segment Analysis
    • 1. Segment Forecasts
    • 2. Antisense Therapies
    • 3. Gene Therapies
    • 4. Cell Therapies

5. DECISION SUPPORT DATABASES

  • Databases
    • 1. Cancer Cases
    • 2. Prevalence of Arthritis
    • 3. Prevalence of Multiple Sclerosis
    • 4. Prevalence of Cardiovascular Diseases
    • 5. Pharma Government Biotech R&D Investment
Back to Top